NUVB Historical PE Ratio Notes

— Nuvation Bio (ticker symbol NUVB) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, targeting some of the most difficult-to-treat tumors. The company's approach involves innovative drug discovery & development, aiming to address significant unmet needs in oncology. Because Nuvation Bio is in early stages without any commercialized products, it generates little to no revenue, while consistently investing heavily in R&D to advance its drug pipeline. As a result, the company typically posts negative earnings per share (EPS), which directly impacts its historical price-to-earnings (PE) ratio. In many historical PE charts & tables, you'll likely see a ȁcnot meaningfulȁd or undefined PE ratio for NUVB, since a negative or zero denominator (earnings) makes the calculation not applicable. Where a ratio is shown, it may fluctuate drastically or seem artificially inflated during brief quarters of small earnings or accounting changes. For companies like Nuvation Bio, it's more useful to focus on pipeline progress, funding runway, and milestones, rather than traditional PE-based valuation metrics. Understanding this context helps interpret NUVB's historical valuation data as a function of its developmental stage rather than its operational profitability.

On this page we presented the Nuvation Bio Historical PE Ratio information for Nuvation Bio' stock. The average NUVB historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 110.2. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average NUVB historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this NUVB historical PE result, against the recent PE: when this page was posted on 5/7/2026, the most recent closing price for NUVB had been 4.81, and the most recent quarterly earnings result, annualized, was 0.04. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent NUVB PE on 5/7/2026 based on annualized quarterly EPS was 120.3. Based on NUVB's history, that recent PE is elevated relative to the historical average, with the recent PE 9.2% higher than the historical average PE across our data set for Nuvation Bio.

For self directed investors doing their due diligence on NUVB or any other given stock, valuation analysis for NUVB can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Nuvation Bio PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for NUVB. Thanks for visiting, and the next time you need to research NUVB Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.